TR200200082T2 - Treating chronic pain using MEK inhibitors. - Google Patents

Treating chronic pain using MEK inhibitors.

Info

Publication number
TR200200082T2
TR200200082T2 TR2002/00082T TR200200082T TR200200082T2 TR 200200082 T2 TR200200082 T2 TR 200200082T2 TR 2002/00082 T TR2002/00082 T TR 2002/00082T TR 200200082 T TR200200082 T TR 200200082T TR 200200082 T2 TR200200082 T2 TR 200200082T2
Authority
TR
Turkey
Prior art keywords
chronic pain
treating chronic
mek inhibitors
formula
mek
Prior art date
Application number
TR2002/00082T
Other languages
Turkish (tr)
Inventor
Dixon Alistair
Lee Kevin
Denham Pinnock Robert
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200200082T2 publication Critical patent/TR200200082T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)

Abstract

Bulus formül (I) ve formül I(A)'dan seçilen bir bilesik kullanilarak kronik agrinin tedavi edilmesi için olan bir yöntemle ilgilidir.The invention relates to a method for treating chronic pain using a compound selected from formula (I) and formula I (A).

TR2002/00082T 1999-07-16 2000-07-05 Treating chronic pain using MEK inhibitors. TR200200082T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
TR200200082T2 true TR200200082T2 (en) 2002-04-22

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00082T TR200200082T2 (en) 1999-07-16 2000-07-05 Treating chronic pain using MEK inhibitors.

Country Status (16)

Country Link
EP (1) EP1202726A2 (en)
JP (1) JP2003504400A (en)
KR (1) KR20020012315A (en)
CN (1) CN1373660A (en)
AR (1) AR024732A1 (en)
AU (1) AU5786000A (en)
CA (1) CA2374052A1 (en)
CO (1) CO5300398A1 (en)
HU (1) HUP0202623A3 (en)
IL (1) IL147619A0 (en)
NZ (1) NZ515567A (en)
PE (1) PE20010545A1 (en)
PL (1) PL352684A1 (en)
TR (1) TR200200082T2 (en)
WO (1) WO2001005392A2 (en)
ZA (1) ZA200109907B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
BRPI0412851A (en) 2003-07-24 2006-10-03 Warner Lambert Co n-methyl-substituted benzamidazoles
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1676837A4 (en) * 2003-10-08 2008-09-10 Teijin Pharma Ltd Process for producing aminopyrrolidine derivative and intermediate compound
BRPI0415710A (en) 2003-10-21 2006-12-19 Warner Lambert Co polymorphic forms of n - [(r) -2,3-dihydroxypropoxy] -3,4-difluoro-2- (2-fluoro-4-yl dophenylamino) benzamide
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
TWI361066B (en) * 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
CN102898364A (en) 2005-05-18 2013-01-30 阵列生物制药公司 Heterocyclic inhibitors of MEK and methods of use thereof
CN103524392B (en) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 As for treating the azetidine of the MEK inhibitor of proliferative disease
CN101511842B (en) 2006-07-06 2012-10-31 阵列生物制药公司 Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006032A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE532789T1 (en) 2006-07-06 2011-11-15 Array Biopharma Inc DIHYDROTHIENOPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
ES2703723T3 (en) 2006-12-14 2019-03-12 Exelixis Inc Methods for using MEK inhibitors
SI2173723T1 (en) 2007-07-05 2011-12-30 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
JP5346345B2 (en) 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
EP2240455B1 (en) 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
JP5760010B2 (en) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド 1- (5-tert-butyl-2-phenyl-2H-pyrazol-3-yl) -3- [2-fluoro-4- (1-methyl-2-oxo-2,3-dihydro-1H-imidazo [ 4,5-B] pyridin-7-yloxy) -phenyl] -urea and related compounds and their use in therapy
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
ES2620644T3 (en) 2011-04-01 2017-06-29 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
KR20140022053A (en) 2011-04-01 2014-02-21 제넨테크, 인크. Combinations of akt and mek inhibitor compounds, and methods of use
HRP20180670T1 (en) 2012-10-12 2018-07-13 Exelixis Inc. NEW PROCEDURE FOR OBTAINING COMPOUNDS FOR THE USE OF CANCER TREATMENT
EP3043790B1 (en) * 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10040769B2 (en) 2015-10-27 2018-08-07 Regenacy Pharmaceuticals, Llc HDAC inhibitors for the treatment of diabetic peripheral neuropathy
HUE055738T2 (en) * 2017-10-17 2021-12-28 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
WO2020259787A1 (en) * 2019-06-28 2020-12-30 University Of Copenhagen Treatment of cns disorders with sleep disturbances

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU757046B2 (en) * 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
JP2002509536A (en) * 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー 2- (4-bromo or 4-iodophenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL143236A0 (en) * 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors

Also Published As

Publication number Publication date
PL352684A1 (en) 2003-09-08
AU5786000A (en) 2001-02-05
HUP0202623A3 (en) 2003-03-28
CA2374052A1 (en) 2001-01-25
AR024732A1 (en) 2002-10-23
KR20020012315A (en) 2002-02-15
HUP0202623A2 (en) 2002-11-28
CN1373660A (en) 2002-10-09
WO2001005392A2 (en) 2001-01-25
NZ515567A (en) 2004-03-26
ZA200109907B (en) 2003-02-28
PE20010545A1 (en) 2001-06-04
JP2003504400A (en) 2003-02-04
WO2001005392A3 (en) 2001-07-19
EP1202726A2 (en) 2002-05-08
IL147619A0 (en) 2002-08-14
CO5300398A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
TR200200205T2 (en) Treating chronic pain using MEK inhibitors
WO2001005392A3 (en) Method for treating chronic pain using mek inhibitors
BR0208105A (en) Metalloproteinase Inhibitors
BR9806752A (en) Phthalazinones.
ATE228111T1 (en) M-AMIDINOPHENYL ANALOGAS AS FACTOR XA INHIBITORS
TR199801255T2 (en) Vitronectin receptor antagonists.
ID27838A (en) 1,2,3,4-TETRAHIDROKINOLIN INHIBITORS 2-SUBSTITUTED 4-AMINO AS CETP INHIBITORS
DK0840732T3 (en) Substituted benzolactam compounds as substance P antagonists
ID18142A (en) 1,4-HETEROSICLIC METALOPROTEASE INHIBITORS
DK0971713T3 (en) Use of cholinesterase inhibitors to treat attention disorders
ATE248161T1 (en) 2-AMINOPYRIDINE CONTAINING CONDENSED CYCLIC SYSTEMS AS NOS INHIBITORS
BR9810459A (en) nitric salts of ace inhibitors
NO20003018D0 (en) Triazinangiogenese inhibitors
ATE234091T1 (en) THROMBIN INHIBITORS
PE20011085A1 (en) ISOXAZOLQUINOLIN OR IMIDAZOLQUINOLIN COMPOUNDS AS INHIBITORS OF MULTI-DRUG RESISTANT PROTEIN
DE69812634D1 (en) Metalloproteinase inhibitors
TR200003859T2 (en) Amidino and guanidino azetidinone triptase inhibitors
PT941975E (en) CEMENT FOR INJECTION CONTAINING CORROSION INHIBITORS
ATE228760T1 (en) THROMBIN INHIBITORS
MX9801190A (en) Prolylendopeptidase inhibitors.
DK1377574T3 (en) 6-phenylbenzonaphthyridines
TR200001819T2 (en) COPD treatment method.
TR200003704T2 (en) Increasing acetylcholine levels
CA2261802A1 (en) Use of xanomeline for treating bipolar disorder
EP1086261A4 (en) ANTI-CORROSION TREATMENT